TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the […]
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage […]
Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders
Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A.Registered Address: 2, Rue du Fort […]
Millicom’s Nomination Committee’s proposal for Board of Directors
Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting […]
Beam Global Reports Record Year End 2023 Operating Results
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative […]
James River Completes Sale of Casualty Reinsurance Business to Fleming Holdings
PEMBROKE, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) […]
Beam Global to Release 2023 Operating Results, Conference Call Scheduled for April 17, 2024 at 4:30 p.m. ET
SAN DIEGO, Calif., April 16, 2024 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), a leading provider of […]
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public […]
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between […]
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision […]
